Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

This study is testing a combination of two drugs — savolitinib (which blocks a cancer-driving protein called MET) and durvalumab (an immunotherapy drug) — in people with advanced stomach cancer that has a specific genetic amplification in the MET gene. **You may be eligible if...** - You are 19 or older with advanced gastric (stomach) cancer that has progressed during or after 1–2 prior chemotherapy regimens - Your cancer has been shown to have MET gene amplification on a genetic test (copy number 4 or higher) - You have at least one measurable tumor on imaging - Your general health score is 0–1 and life expectancy is at least 3 months - Your body weight is over 30 kg **You may NOT be eligible if...** - Your cancer does not have MET amplification - You have not had a sufficient washout period from prior therapies - Your organ function does not meet the required minimums - You have serious uncontrolled health conditions Talk to your doctor to see if this trial is right for you.